Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Entrada Therapeutics, Inc. (NASDAQ: TRDA) on behalf of investors. This investigation follows a significant stock price drop of 57.27% on May 7, 2026, after the company announced "positive" Phase 1/2 clinical study results that showed a very small increase in dystrophin production, deemed insufficient to make the drug competitive. The law firm is encouraging affected investors to contact them for more information and to assist in the investigation.
Understanding Momentum Shifts in (TRDA)
This article analyzes Entrda Therapeutics Inc. (NASDAQ: TRDA) using AI models, highlighting strong sentiment across all horizons supporting an overweight bias. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths and support/resistance levels.
Price to book forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA
This article displays the "Price to book forward" metric for Entrada Therapeutics, Inc. (NASDAQ: TRDA). It appears to be a financial data point presented within the TradingView platform, with no additional textual analysis or details provided. The content is minimalist, focusing solely on the presentation of this specific financial ratio for the company.
Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA
This article provides a brief financial overview for Entrada Therapeutics, Inc. (NASDAQ: TRDA), focusing on its forward price-to-earnings ratio. The content primarily lists navigation and platform features of TradingView, where this financial data is presumably presented, rather than offering detailed analysis or specific figures.
Price to sales forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA
This page provides financial information for Entrada Therapeutics, Inc. (NASDAQ: TRDA) on TradingView, specifically focusing on its price-to-sales forward ratio. It also lists various features and services offered by TradingView, including market data, analytical tools, community features, and business solutions.
Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA)
This article provides an overview of Entrada Therapeutics, Inc. (NASDAQ: TRDA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and past financial results, alongside information on employee count and EBITDA.
TRDA Forecast — Price Target — Prediction for 2027
This article provides a forecast for Entrada Therapeutics, Inc. (TRDA) stock, including current analyst price targets, ratings, and financial data. It details the company's stock performance, market capitalization, earnings, revenue, and EBITDA, along with frequently asked questions regarding its stock price, volatility, and future outlook. The article emphasizes that the information is not investment advice and encourages readers to conduct their own research.
TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of Entrada Therapeutics Inc (TRDA), detailing its revenue breakdown, profitability margins, and a competitive comparison. TRDA boasts a strong gross margin of 100.00% but shows negative operating and net margins, indicating challenges in converting operational activities into profit. It also compares TRDA's market capitalization and gross margin against competitors such as SABS and FHTX to benchmark its performance.
Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Entrada Therapeutics Inc (TRDA), highlighting its current valuation score of 6.99 within the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -1.77, which is significantly below its recent high. The article also mentions that relevant data for P/B, P/S, and P/CF ratios have not been disclosed by the company.
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of Entrada Therapeutics Inc.'s (TRDA) revenue breakdown. It indicates that relevant data for business segments and profit contribution have not yet been disclosed by the company. However, it does provide a revenue figure for the United States region.
Avoiding Lag: Real-Time Signals in (TRDA) Movement
This article analyzes Entrada Therapeutics Inc. (
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Entrada Therapeutics Inc (TRDA) has an earnings forecast score of 8.50, ranking 107th in its industry, with an average analyst price target of $16.50. Analysts predominantly rate TRDA as a "Buy," forecasting an expected revenue of 411.43K for the next quarter and an EPS of -$1.05.
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis
Entrada Therapeutics Inc (TRDA) currently holds a financial score of 6.01, ranking 301st out of 388 in the Biotechnology & Medical Research industry, indicating stable financial health but low operating efficiency. The company's latest quarterly revenue decreased by 95.74% year-over-year, and its net profit saw a 128.93% year-over-year decline. The analysis provides scores for various financial dimensions but notes that relevant detailed data has not yet been disclosed by the company.
Entrada Therapeutics Stockholders Approve Directors and Equity Plans
Entrada Therapeutics Inc. stockholders approved key measures at their annual meeting, including the election of two Class II directors, Peter S. Kim, Ph.D., and Bernhardt Zeiher, M.D., and the ratification of Ernst & Young LLP as their independent auditor. Shareholders also approved amendments to equity incentive and employee stock purchase plans to better attract and retain talent. TipRanks' AI Analyst, Spark, rates TRDA as Neutral due to financial performance concerns despite positive corporate updates.
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity
Entrada Therapeutics director and 10% owner Kush Parmar was granted 19,000 stock options with an exercise price of $5.97 per share, expiring on June 10, 2036. These options will vest on the earlier of the one-year anniversary of June 10, 2026, or the company’s next annual meeting. This transaction was reported on a Form 4 filing, indicating a neutral impact and sentiment.
Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97
Entrada Therapeutics (TRDA) director Gina Chapman was granted 19,000 stock options at an exercise price of $5.97 per share. These options will vest on the earlier of one year from June 10, 2026, or the company's next annual meeting, and are set to expire on June 10, 2036. The transaction was reported as a compensation award rather than a market purchase, as detailed in a Form 4 SEC filing.
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity
Entrada Therapeutics director Mary Thistle received a stock option grant for 19,000 shares of common stock, with an exercise price of $5.97 and an expiration date of June 10, 2036. This compensation-related grant vests on the earlier of one year from June 10, 2026, or the company’s next annual meeting. The transaction is not an open-market trade, and after this grant, Thistle directly holds 19,000 stock options.
Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading
Entrada Therapeutics director Radhakrishnan Maha was granted 19,000 stock options, allowing him to purchase common stock at an exercise price of $5.97 per share. These options, granted at no cost, will vest on the earlier of June 10, 2027, or the company's next annual meeting, and expire in 2036. Following this grant, Maha directly holds 19,000 stock options in Entrada Therapeutics ($TRDA).
Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options
Entrada Therapeutics director Peter S. Kim received a grant of 19,000 stock options with an exercise price of $5.97 per share, expiring on June 10, 2036. These options vest on the earlier of June 10, 2027, or the company's next annual meeting of stockholders. The transaction was reported via a Form 4 SEC filing, detailing the compensation in the form of derivative securities.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)
This article highlights contrasting analyst sentiments for Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) within the healthcare sector. Entrada Therapeutics receives a Strong Buy consensus with significant upside potential, based on a Buy rating from Guggenheim and Roth MKM. In contrast, Pfizer holds a Hold consensus rating with a more modest upside, influenced by Hold ratings from Bernstein and Citi.
Discipline and Rules-Based Execution in TRDA Response
This article provides an in-depth analysis of Entrada Therapeutics Inc. (NASDAQ: TRDA) as of June 7, 2026, highlighting weak near-term sentiment but strong mid and long-term signals. It presents AI-generated trading strategies including position, momentum, and risk hedging, along with multi-timeframe signal analysis to guide traders on optimal entry and exit points. The analysis emphasizes disciplined, rules-based execution with specific support and resistance levels.
Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)
Oppenheimer reiterated a Buy rating on Entrada Therapeutics Inc (TRDA) with a price target of $23.00, while Roth MKM also maintained a Buy rating with a $10.00 price target. The company reported a Q1 revenue of $875 thousand and a GAAP net loss of $39.72 million. Insider sentiment is positive, with a director recently purchasing 5,000 shares.
Entrada Therapeutics (NasdaqGM:TRDA) Stock Forecast & Analyst Predictions
Entrada Therapeutics (TRDA) is expected to see its earnings decline by 1.6% per annum, while revenue is projected to grow by 44% yearly. Analysts forecast a net loss per share of US$4.09 next year, leading to a recent consensus price target reduction to US$18.75. The company is actively progressing its Duchenne muscular dystrophy pipeline with several clinical trials, including ELEVATE-45-201 and ELEVATE-44-201, and has a strong cash position to fund operations through Q3 2027.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
Pomerantz LLP is investigating potential securities fraud claims against Entrada Therapeutics, Inc. (TRDA) on behalf of investors. This investigation follows a significant stock price drop after Entrada announced Phase 1/2 clinical study results for a Duchenne treatment, which, despite being characterized as "positive," showed a dystrophin production increase less than what is considered competitive. Investors are encouraged to contact Pomerantz LLP to explore joining a potential class action.
Entrada gets clearance to escalate dose in DMD trial
Entrada Therapeutics Inc. (NASDAQ:TRDA) has received clearance from an independent Data Monitoring Committee to escalate the dose in Cohort 2 of its ELEVATE-45-201 study for Duchenne muscular dystrophy (DMD) to 10 mg/kg, up from 5 mg/kg. The decision follows a review of safety and pharmacokinetic data from the first cohort. The company expects to report safety, early pharmacokinetic, and dystrophin data from Cohort 1 in mid-2026, with subsequent data from Cohorts 2 and 3 to follow.
Safety committee approves higher 10 mg/kg dose for Entrada's Duchenne muscular dystrophy trial
Entrada Therapeutics has announced that an independent Data Monitoring Committee has approved an increase in the dose to 10 mg/kg for Cohort 2 in its Phase 1/2 trial for Duchenne muscular dystrophy. This decision follows positive safety and pharmacokinetic reviews of subjects treated with 5 mg/kg in Cohort 1. The company aims to report Cohort 1 data by mid-2026 and expects subsequent data from higher doses to follow, with the goal of improving patient outcomes.
Rare disease trial tests DMD treatment with once-every-six-week dosing
Entrada Therapeutics announced that an independent Data Monitoring Committee recommended escalating the dose of ENTR-601-45 to 10 mg/kg for Cohort 2 in its Phase 1/2 ELEVATE-45-201 study for Duchenne muscular dystrophy. All eight participants from Cohort 1, who received 5 mg/kg, have advanced to the open-label Phase 2 portion. The company anticipates sharing safety, pharmacokinetic, and dystrophin data from Cohort 1 in mid-2026, highlighting a once-every-six-week dosing regimen that could reduce treatment burden.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics announced granting 18,600 restricted stock units (RSUs) to three new non-executive employees under its 2025 Inducement Equity Plan. These grants, effective June 1, 2026, were approved by the Compensation Committee as a material inducement for their employment, complying with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over time, subject to continuous service with the company.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics, Inc. announced incentive grants totaling 18,600 restricted stock units (RSUs) to three new non-executive employees. These grants, effective June 1, 2026, were approved by the Compensation Committee under the Company's 2025 Inducement Equity Plan to attract new talent. The RSUs will vest over time, with a quarter vesting on the one-year anniversary and the remainder quarterly thereafter.
TRDA - Early Genetic Medicine Pipeline And Cash Runway Will Support Long Term Neuromuscular Opportunity
Entrada Therapeutics (TRDA) is a clinical-stage biopharma company focusing on genetic medicines for neuromuscular and ocular conditions. The company's early-stage clinical data for ENTR-601-44 in Duchenne muscular dystrophy (DMD) shows promise with functional improvements and a clean safety profile, pointing to a potential path for tailored therapies. Entrada's robust pipeline, including exon skipping therapies and a partnership with Vertex, along with a cash runway extending into late 2027, positions it for long-term growth in the neuromuscular disease market.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
Pomerantz LLP is investigating potential securities fraud claims against Entrada Therapeutics, Inc. (NASDAQ: TRDA) on behalf of its investors. This investigation follows a significant stock price drop after the company announced Phase 1/2 clinical study results for a Duchenne muscular dystrophy drug candidate, which showed a dystrophin increase deemed insufficient by the firm. Investors are encouraged to contact Pomerantz LLP for information regarding a potential class action.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Entrada Therapeutics, Inc. (TRDA) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Entrada Therapeutics, Inc. (NASDAQ:TRDA) following a significant stock price drop. The investigation stems from an announcement of Phase 1/2 clinical study data for a Duchenne treatment, which despite being characterized as "positive," showed only a 2.36% increase in dystrophin production, rendering the drug potentially uncompetitive. Shareholders who purchased Entrada securities are encouraged to contact the firm to assist in the investigation.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Entrada Therapeutics, Inc. (TRDA) following a significant drop in its stock price. This decline occurred after the company released Phase 1/2 clinical study data for its Duchenne muscular dystrophy treatment, which, despite being called "positive," showed only a 2.36% increase in dystrophin production, deemed insufficient to compete with other therapies. The law firm is encouraging shareholders to join the investigation, operating on a contingency fee basis.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Entrada Therapeutics, Inc. (TRDA) following a significant stock price drop on May 7, 2026. This decline occurred after the company announced "positive" Phase 1/2 clinical study data for a Duchenne muscular dystrophy drug, which showed an increase in dystrophin production far less than what is considered necessary to compete with existing treatments. Investors who purchased Entrada securities are encouraged to contact the firm to learn more and potentially assist in the investigation.
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Entrada Therapeutics, Inc. (NASDAQ:TRDA) after the company announced "positive" Phase 1/2 clinical study results for a Duchenne muscular dystrophy drug. The investigation stems from a significant drop in Entrada's stock price following the announcement, as the reported 2.36% increase in dystrophin production was deemed insufficient to make the drug competitive. Shareholders are encouraged to contact the firm for further information regarding the securities investigation.
TRDA - Entrada Therapeutics Inc Stock Price and Quote
This page provides a detailed financial overview of Entrada Therapeutics Inc. (TRDA), including its stock price, key financial metrics, recent news, analyst ratings, and insider trading activity. The company is a clinical-stage biopharmaceutical firm focused on developing therapeutics for neuromuscular and ocular diseases using its Endosomal Escape Vehicle (EEV) platform. Recent news highlights include disappointments in Duchenne Muscular Dystrophy (DMD) drug efficacy and subsequent stock drops, alongside past financial results and clinical trial updates.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Entrada Therapeutics, Inc. (TRDA) following a significant drop in its stock price. This decline occurred after the company announced "topline data" from a clinical study, which showed a 2.36% increase in dystrophin production, deemed insufficient to be competitive. Shareholders who purchased Entrada securities are encouraged to contact the firm to learn more and potentially assist in the investigation.
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock
Bernhardt G. Zeiher, a director at Entrada Therapeutics (NASDAQ:TRDA), purchased 5,000 shares of the company's common stock for $29,316 on May 20, 2026, at prices between $5.86 and $6.00 per share. This transaction increases his indirect ownership to 5,000 shares, occurring while the stock is down 41% year-to-date and indicates an oversold condition. Entrada Therapeutics is also preparing to announce topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44.
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock
Bernhardt G. Zeiher, a director at Entrada Therapeutics (NASDAQ:TRDA), recently purchased 5,000 shares of the company's stock for $29,316. The transaction was made indirectly through his revocable living trust at prices ranging from $5.86 to $6.00 per share. This purchase occurs while the stock is trading at $6.31, down 41% year-to-date, and is considered undervalued according to InvestingPro analysis, with the RSI indicating oversold conditions.
Entrada Therapeutics (TRDA) director’s trust buys 5,000 common shares
A revocable living trust associated with Entrada Therapeutics director Bernhardt G. Zeiher purchased 5,000 shares of TRDA common stock. The open-market transaction occurred at a weighted average price of $5.8632 per share, with individual trades ranging from $5.86 to $6.00. Following this purchase, the trust indirectly holds 5,000 shares, and Dr. Zeiher disclaims beneficial ownership beyond pecuniary interest.
Entrada Therapeutics Reports Positive Phase 1/2 Results for ENTR-601-44 in Duchenne Muscular Dystrophy, Highlighting Best-in-Class Potential and $5B U.S. Market Opportunity 679
Entrada Therapeutics announced significant progress in its genetic medicines pipeline, especially with positive Phase 1/2 results for ENTR-601-44 in Duchenne Muscular Dystrophy, showing strong functional benefits and a favorable safety profile. The company projects a $5 billion annual U.S. market opportunity for DMD and has a cash runway into Q3 2027, supported by strategic partnerships and multiple upcoming data readouts in 2026. Entrada's differentiated EEV platform and expanding pipeline across DMD, DM1, and inherited retinal diseases position it for substantial growth and shareholder value creation.
INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC has initiated an investigation into Entrada Therapeutics, Inc. (TRDA) to determine if the company violated federal securities laws. This investigation follows a drop in Entrada's stock price after the announcement of Duchenne muscular dystrophy study results, which showed dystrophin increase below analyst expectations. Shareholders who suffered losses are encouraged to contact the law firm to discuss their legal rights.
Entrada Therapeutics (TRDA) furnishes updated corporate presentation to investors
Entrada Therapeutics (TRDA) has filed an 8-K to provide investors and analysts with an updated corporate presentation, dated May 2026. This presentation, furnished under Regulation FD, details the company's clinical-stage programs, including five in Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1), and highlights several clinical data catalysts expected in 2026, alongside their financial position. The report emphasizes the favorable safety profile and early functional benefits observed in their ELEVATE-44-201 study for DMD, as well as the de-risking of their neuromuscular portfolio.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Entrada Therapeutics, Inc. (TRDA) following a significant stock price drop. This drop occurred after the company announced "positive" Phase 1/2 clinical study results for its Duchenne Multiple Ascending Dose (MAD) treatment, which showed only a 2.36% increase in dystrophin production, deemed insufficient to be competitive. The firm encourages shareholders who purchased Entrada securities to contact them for more information regarding the potential claims.
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Entrada Therapeutics, Inc. (TRDA) for potential securities fraud. Investors who have experienced losses with TRDA are encouraged to contact the firm, as they may have the opportunity to join a class action lawsuit to recover damages. The investigation seeks to determine if the company violated securities laws.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Entrada Therapeutics, Inc. (TRDA) on behalf of investors who purchased its securities. This investigation follows a significant stock price drop after the company announced "topline data" from a clinical study, which showed only a 2.36% increase in dystrophin production—a result considered insufficient for competitive treatment against Duchenne patients. The firm encourages affected stockholders to contact them for more information regarding potential claims.
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Entrada Therapeutics, Inc. (TRDA) for potential securities law violations. This comes after Entrada reported "positive" Phase 1/2 clinical study data on May 7, 2026, which investors perceived as disappointing due to only a slight improvement in protein production for Duchenne patients, leading to a nearly 57.3% stock drop. The firm is now seeking investors who suffered losses to join the fraud investigation.
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Entrada Therapeutics, Inc. (TRDA) on behalf of investors for potential securities law violations. This follows a significant 57.3% stock drop after the company announced "positive" Phase 1/2 clinical study data for its Duchenne muscular dystrophy drug, which showed only a slight increase in a critical protein, falling short of market competitiveness. Shareholders who suffered losses are encouraged to participate in the investigation.
(TRDA) Movement Within Algorithmic Entry Frameworks
This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA) using algorithmic entry frameworks, identifying weak near and mid-term sentiment but a strong long-term outlook. It presents various trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for the stock.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Entrada Therapeutics, Inc. (NASDAQ:TRDA) following a significant drop in stock price. This decline occurred after the company announced "positive" topline data from a Phase 1/2 clinical study, which, despite the characterization, showed a dystrophin production increase significantly below what is needed for the drug to be competitive. The firm encourages affected investors to contact them to learn more about the investigation.
